Skip to content

Pred Forte® versus placebo eye drops in chronic central serous chorioretinopathy trial (PICS trial)

Status
Not yet recruiting
Phases
Phase 3
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-511575-15-00
Enrollment
40
Registered
2025-01-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central serous chorioretinopathy

Brief summary

Change in sub- and intraretinal fluid on OCT scan: The primary outcome measure of this study is the effect of steroid eye drops in cCSC on the amount of sub and intraretinal fluid. The difference in the amount of sub- and intraretinal fluid will be compared between the OCT scan made prior to the study and the OCT scan made at the second consultation after the study medication has been used for four weeks.

Interventions

DRUGDURATEARS
DRUGPred Forte 1
DRUG0 % oogdruppels

Sponsors

Stichting Radboud University Medical Center
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Change in sub- and intraretinal fluid on OCT scan: The primary outcome measure of this study is the effect of steroid eye drops in cCSC on the amount of sub and intraretinal fluid. The difference in the amount of sub- and intraretinal fluid will be compared between the OCT scan made prior to the study and the OCT scan made at the second consultation after the study medication has been used for four weeks.

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026